Vascular and Metabolic Effects of Rosuvastatin

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01660919

Enrollment

160

Registered

2012-08-09

Start date

2011-10-31

Completion date

2013-12-31

Last updated

2014-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Keywords

insulin resistance

Brief summary

The investigators hypothesize that rosuvastatin does-dependently worsens insulin sensitivity.

Interventions

DRUGplacebo

DRUGrosuvastatin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

25 Years to 80 Years

Healthy volunteers

Inclusion criteria

* hypercholesterolemia

Exclusion criteria

* overt liver disease, chronic renal failure, hypothyroidism, myopathy, uncontrolled diabetes (HbA1c \> 9%), severe hypertension, stroke, acute coronary events, coronary revascularization within the preceding 3 months, or alcohol abuse

Design outcomes

Primary

Measure	Time frame
flow-mediated dilation	8 weeks of treatment

Secondary

Measure	Time frame
insulin resistance	8 weeks of treatment

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026